Q-omics provides the consensus-scored ZNF710 profile across patient tissues and cancer cell-line models. ZNF710 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF710 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, ZNF710 RNA expression shows 20,258 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRP, and ACC as cancer lineages where ZNF710 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF710 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF710 survival associations across molecular data types. ZNF710 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF710 RNA expression–survival associations across cancer types. High ZNF710 expression shows unfavorable associations in UVM, ACC and CESC, but favorable associations in KIRC, UCS and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF710 RNA expression.
This table summarizes ZNF710 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF710. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF710 shows lower tumor expression in KIRP and higher tumor expression in LIHC, COAD, THCA, STAD and BRCA. The KIRP box plot shows higher ZNF710 RNA expression in normal versus tumor tissue (log2 FC = −0.944, t-test p < 0.001).
This table shows molecular features associated with ZNF710 in patient tissues and cancer cell lines. In patient samples, ZNF710 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF710 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
